Pharmacy最新文献

{"title":"Application of Fuzzy AHP for Medication Decision Making in Iron-Chelating Medications for Thalassemia.","authors":"Saeed Barzegari, Hosein Rostamian, Ehsan Firoozi-Majd, Ibrahim Arpaci","doi":"10.3390/pharmacy13030086","DOIUrl":"10.3390/pharmacy13030086","url":null,"abstract":"<p><p>Iron overload is a significant concern for patients with thalassemia and often necessitates the use of iron-chelating agents to mitigate the associated complications. Selecting the most appropriate chelation therapy from the available options is a complex decision for healthcare professionals. To support this decision-making process, this study investigates the application of the \"Fuzzy Analytic Hierarchy Process\" (FAHP) for medication selection in thalassemia patients requiring iron-chelation therapy. In this study, 20 hematologists participated, and matrices related to the FAHP model were used to evaluate three primary iron chelators: deferoxamine, deferasirox, and deferiprone. The results revealed that deferiprone was the most effective choice, while deferasirox outperformed the others in terms of cost and patient satisfaction. Notably, deferoxamine exhibits the highest rate of side effects, followed by deferiprone and deferasirox. The results obtained from the FAHP analysis indicated a consensus among experts and highlighted deferasirox as the optimal choice for treating chronic iron overload in thalassemia patients. The study demonstrates the practical applicability of the FAHP methodology in guiding informed decisions for iron-chelation therapy. It provides insights to help healthcare professionals optimize treatment strategies for patients with thalassemia.</p>","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"13 3","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12197068/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144486257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insulin Glargine Biosimilar Prescribing and Cost Trends in the United Kingdom's Primary Care from 2020 to 2024.","authors":"Murtada Alsaif, Zoë Blumer","doi":"10.3390/pharmacy13030085","DOIUrl":"10.3390/pharmacy13030085","url":null,"abstract":"<p><strong>Background/objectives: </strong>Long-acting insulin glargine (iGlar) has been available as a biosimilar since 2014 in the UK. We reviewed previous prescribing to evaluate if the anticipated cost savings with biosimilars were realized with iGlar.</p><p><strong>Methods: </strong>This study investigated prescribing patterns of long-acting iGlar (100 units/mL) in cartridges and pre-filled pens from 2020 to 2024 across primary care organizations in England, Northern Ireland, Scotland, and Wales.</p><p><strong>Results: </strong>iGlar prescribing declined in all of the four nations. From 2020 to 2024, the total prescribed quantity of biosimilars persistently increased in all countries, reaching 24% in England, 5% in Northern Ireland, 24% in Scotland, and 11% in Wales, all in 2024. Consequently, the proportion of Lantus prescriptions (as quantity) decreased but continued to exceed that of all available iGlar products combined in all countries in all years analyzed. By 2024, Lantus was also priced lower than the most common biosimilar, Abasaglar, across all nations.</p><p><strong>Conclusions: </strong>The introduction of biosimilars does not automatically result in altered prescribing practices, though we show that the most commonly prescribed iGlar was also the least expensive product at the end of the analysis period. At launch and for several years after, biosimilars failed to gain strong utilization, despite cost advantages, highlighting the need for active switching policies and prescriber engagement.</p>","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"13 3","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12196553/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144486259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Experience of L-Glutamine in Sickle Cell Disease: A Retrospective Observational Study.","authors":"Shouq Turkistani, Atika AlHarbi, Mansoor Khan, Aeshah AlAzmi, Sultan Almutairi, Naglla Elimam, Sultan Alotaibi","doi":"10.3390/pharmacy13030084","DOIUrl":"10.3390/pharmacy13030084","url":null,"abstract":"<p><p>Sickle cell disease (SCD) affects millions globally, with approximately 0.26% of the Saudi population impacted. Despite standard treatments, patients frequently experience vaso-occlusive crises (VOCs). This retrospective observational study evaluated the real-world effectiveness of L-glutamine (Endari^®) in reducing SCD-related complications in the Saudi population, where data remain limited. Patients aged five and older who received L-glutamine from June 2019 to June 2023 were included. The primary endpoint was VOC frequency through week 48. Descriptive statistics and paired t-tests compared outcomes before and after treatment. Fifteen patients (median age 12 years, 53% female) met the inclusion criteria; all were on maximum tolerated hydroxyurea. Eleven completed 48 weeks, showing a median VOC reduction from 4 to 3 (<i>p</i> = 0.44). Hospital stay duration remained unchanged (median 7 days, <i>p</i> = 0.72). Laboratory parameters were largely stable, except for a 61.9% increase in reticulocyte count (<i>p</i> = 0.03). The estimated annual treatment cost exceeded SAR 2 million (USD ~547,840). L-glutamine did not produce statistically significant improvements in VOC frequency, though numerical trends were observed. Given the small sample size and limited statistical power, the findings are exploratory. Larger, well-powered, multicenter studies are needed to confirm L-glutamine's potential benefits in this population.</p>","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"13 3","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12197130/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144486268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Evidence Assessing the Safety of Administering Intravenous Rituximab Biosimilar in the First Cycle and Subcutaneous Rituximab in Subsequent Cycles in B-Cell Lymphoma Patients.","authors":"Tamather Almandeel, Mansoor Ahmed Khan, Ashwag Algethami, Mashael S Alaboud, Munirah A Alkathiri, Mohammed Aseeri, Ahmed Absi, Mubarak Almansour, Abdullah Alotaibi","doi":"10.3390/pharmacy13030083","DOIUrl":"10.3390/pharmacy13030083","url":null,"abstract":"<p><p><b>Background:</b> Biosimilar versions of rituximab have similar safety and efficacy as the reference product across all indications based on the extrapolation principle. Our organization replaced intravenous (IV) rituximab (Mabthera) with IV rituximab (Truxima-Biosimilar) in 2021. Hence, our practice changed to providing first cycles of IV rituximab (Truxima-Biosimilar) instead of rituximab (Mabthera), and if the first cycle was completed without severe infusion-related reactions (IRRs), then subsequent cycles were given with subcutaneous (SC) rituximab as per institutional guidelines. However, the safety of this approach has not been evaluated. <b>Methods:</b> A retrospective study was conducted at the Princess Nourah Oncology Center in Saudi Arabia. The primary objective was to assess IRRs after using IV rituximab (Truxima-Biosimilar) in the first cycle followed by SC rituximab in subsequent cycles. <b>Results:</b> Of the 71 patients reviewed, 35 patients met the eligibility criteria. Only one (3%) patient developed an IRR. However, it was a Grade 1 IRR, as per CTCAE.V5, and the patient was able to complete the remaining IV infusion successfully. Hence, all patients transitioned from IV rituximab biosimilar to SC rituximab Mabthera. <b>Conclusions:</b> This real-world study demonstrates that transitioning from IV rituximab biosimilar to SC Mabthera is a well-tolerated and safe practice, confirming the extrapolation principle of biosimilars.</p>","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"13 3","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12196662/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144486267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potentially Inappropriate Medication Use Among Older Adults with Cognitive Impairment and Dementia Attending Primary Care-Based Memory Clinics.","authors":"Rishabh Sharma, Linda Lee, Feng Chang, Tejal Patel","doi":"10.3390/pharmacy13030082","DOIUrl":"10.3390/pharmacy13030082","url":null,"abstract":"<p><p>Potentially inappropriate medications (PIMs) increase the risk of adverse drug reactions, hospitalizations, and worsened health outcomes in older adults, particularly those with cognitive impairment (CI) or dementia. This study was designed to compare the Beers Criteria^® 2023 and the Screening Tool of Older Persons' Potentially Inappropriate Prescriptions (STOPP) Criteria 2023 to determine which identifies a higher prevalence of PIMs in older adults with CI or dementia attending primary care-based memory clinics. PIMs were identified with the use of the updated Beers Criteria^® 2023 and STOPP Criteria 2023, from electronic medical records of study participants from January to August 2023. The study identified PIMs and analyzed associated risk factors using bivariate logistic regression. Of 44 older adults, 47.7% (n = 21) were detected with one PIM based on Beers Criteria^® 2023, and 27.2% (n = 12) were identified with at least one PIM using STOPP criteria. Using the updated Beers Criteria^® 2023 and STOPP Criteria 2023, the study identified 50 PIMs (averaging 0.9 PIMs per participant) based on Beers Criteria^® and 31 PIMs (averaging 0.6 PIMs per participant) based on STOPP Criteria, respectively. Bivariate logistic regression revealed a significant association between having nine or more comorbidities and PIMs according to Beers Criteria^® (odds ratio (OR) = 8.4, 95% confidence interval (CIn) = 1.27-55.39, <i>p</i> = 0.027). This study highlights the high prevalence of PIMs among older adults with CI or dementia, emphasizing the need for regular medication reviews. Implementing both criteria can enhance medication management and improve patient safety in this vulnerable population.</p>","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"13 3","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12196525/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144486265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Jamaican Community Pharmacists-Determined Barriers to Availability of Smoking Cessation Aids.","authors":"Aleena Langlay, Jeanine Abrons, Andrea Daly","doi":"10.3390/pharmacy13030081","DOIUrl":"10.3390/pharmacy13030081","url":null,"abstract":"<p><strong>Objectives: </strong>To determine the willingness of Jamaican pharmacists to stock and dispense smoking cessation aids and determine barriers to selling products.</p><p><strong>Design: </strong>A descriptive study that utilized pharmacist-completed surveys. The participants received a sectionalized survey and a structured questionnaire tool. Data collection took place over six weeks.</p><p><strong>Setting: </strong>Pharmacists practicing in pharmacies registered by the Pharmacy Council of Jamaica (PCJ) Participants: A total of fifty-seven registered community pharmacists.</p><p><strong>Results: </strong>Most pharmacies (87.7%) do not stock smoking cessation aids. The most identifiable products were nicotine patches/nicotine gum. Pharmacists' barriers to selling were cost (42%), lack of knowledge of the process of obtaining cessation aids (27.3%), and low demand from patients/clients (22.7%). Most pharmacists (86%) were willing to stock cessation aids. Of the total product requests, 61.2% were lodged by persons 26-50 years old. The stocking of products was not independent of location (<i>p</i> < 0.005).</p><p><strong>Conclusion: </strong>The barriers to the availability of smoking cessation aids, once adequately addressed, could positively enhance the achievement of smoking cessation practices.</p>","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"13 3","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12196336/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144486260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Qualitative Analysis of Test-to-Treat Benefits and Barriers for Pharmacists in Rural Washington State.","authors":"Bradley Brown, Megan Undeberg, Angela Stewart, Kimberly McKeirnan","doi":"10.3390/pharmacy13030080","DOIUrl":"10.3390/pharmacy13030080","url":null,"abstract":"<p><strong>Background: </strong>Rural communities in the United States experience significant barriers in accessing healthcare, including inadequate numbers of providers and local healthcare facilities. These barriers are exacerbated during seasons with high rates of respiratory diseases when rural clinics and providers may be overwhelmed. When mild, many of these respiratory diseases may be managed effectively in alternate settings, including community pharmacies. Investigators interviewed pharmacists in Washington State to explore the capacity of pharmacists and pharmacies to provide test-to-treat services for COVID-19, influenza, and strep throat.</p><p><strong>Methods: </strong>A qualitative study design was used to conduct key informant interviews with pharmacists who precepted student pharmacists from a local university. Twenty interviews were conducted, transcribed, and qualitatively evaluated to identify themes. The 5 A's of Access were utilized as a theoretical framework. This framework describes five domains of access, including affordability, availability, accessibility, accommodation, and acceptability.</p><p><strong>Results: </strong>Qualitative analysis identified several themes that described the benefits of offering test-to-treat services in rural communities, such as reducing geographical barriers to accessing care, reducing wait times for patients, and reducing the number of patients seeking higher levels of care for basic treatments. Barriers to offering test-to-treat services identified by pharmacist participants included difficulties with receiving payment for services, challenges with adequate staffing, and the lack of awareness among many people in rural communities that pharmacies offer test-to-treat services.</p><p><strong>Conclusions: </strong>Rural communities experience challenges with the limited capacity of healthcare providers to meet the needs of patients in their communities. The results of this qualitative analysis may be useful to pharmacists in U.S. states where collaborative drug therapy agreements or collaborative practice agreements allow the provision of test-to-treat services. By providing test-to-treat services, pharmacists can increase access to care for rural patients and alleviate the burden of offering these services from other healthcare providers.</p>","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"13 3","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12197254/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144486266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Knowledge, Attitudes, and Practices Toward Self-Medication Among Pharmacy Undergraduates in Penang, Malaysia: A Cross-Sectional Study.","authors":"Bayan F Ababneh, Hisham Z Aljamal, Rabia Hussain","doi":"10.3390/pharmacy13030079","DOIUrl":"10.3390/pharmacy13030079","url":null,"abstract":"<p><strong>Background: </strong>Self-medication is the use of medicinal products to treat self-diagnosed disorders or symptoms without the prescription or supervision of a healthcare professional. There is a lack of data about self-medication knowledge, attitudes, and practices among pharmacy undergraduates in Malaysia. This study assessed the knowledge, attitudes, and practices among undergraduate pharmacy students in Penang regarding self-medication.</p><p><strong>Method: </strong>A descriptive cross-sectional study was conducted using a self-administered, web-based survey (Google Forms), which was completed and responded to by 203 undergraduate pharmacy students from Penang, Malaysia, between October and December 2023. Descriptive statistics were used to summarize the socio-demographic characteristics of the participants. Associations between the socio-demographic characteristics of the participants and the knowledge, attitudes, and practices regarding self-medication were assessed using a chi-square test. Regression analyses were carried out to determine whether the socio-demographic characteristics of the participants were associated with practices of self-medication.</p><p><strong>Results: </strong>A total of 203 of the undergraduate pharmacy students completed the questionnaire. More than half of the participants' age ranged between 19 and 21 years old, the majority were females (77.3%), and 31.5% of the participants had family members employed in the healthcare sector. Most respondents showed good knowledge in a variety of domains: 97.5% acknowledged the potential for drug interaction with other medications, indicating a high awareness of proper self-medication practices. A positive attitude was found regarding participants' attitudes toward self-medication, and 65.5% practiced self-medication, primarily for treating minor illnesses (75.9%). Common conditions included fever (83.3%), cough/cold/flu (76.8%), and headache (71.4%). Reasons for not self-medicating included the absence of illness (20.2%), lack of knowledge/prior experience (19.2%), and fear of using the wrong medication (18.7%). Only academic year level was the predictor of practicing self-medication within the last six months among the participants.</p><p><strong>Conclusions: </strong>Generally, the participants possessed good knowledge and positive attitudes toward self-medication. The study revealed no significant associations between demographic characteristics and knowledge or attitudes. Insights from this research contribute to understanding self-medication practices among pharmacy students in Penang, informing potential interventions to promote responsible self-medication practices.</p>","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"13 3","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12197184/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144486261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacy Students' Perceptions of Receiving Hands-On Continuous Glucose Monitoring (CGM) Education as Part of Their Core Curriculum: A Pre-Post Study.","authors":"Joyce Y Lee, Daniela Arcos, Daniella Chan, Celine Karabedian, José Mayorga","doi":"10.3390/pharmacy13030078","DOIUrl":"10.3390/pharmacy13030078","url":null,"abstract":"<p><p>Hands-on continuous glucose monitoring (CGM) training is yet to be integrated intentionally into most pharmacy curricula. The objective of this study was to examine pharmacy students' perceptions of receiving hands-on CGM training as part of their core therapeutics in diabetes. Anonymous, voluntary pre-post surveys were administered to two cohorts of 3rd-year pharmacy students from a public pharmacy school in Southern California. Pharmacy students from other class levels were excluded. The surveys, consisting of Likert scale and open-ended questions related to different aspects of CGM, were administered via a web-based learning management system. Descriptive analyses were utilized to summarize the data. In total, 84 (98%) and 79 (92%) students completed the pre- and post-activity surveys, respectively, with an average of 12.5 days of CGM wear. After receiving the CGM training, 94% of the students recommended the integration of hands-on CGM training into the PharmD curriculum. In addition, the number of students who felt confident coaching patients on CGM use more than doubled from 30% to 85%, with 73% reporting added benefits of improved personal health behaviors. In conclusion, pharmacy students' perceptions of integrating hands-on CGM education as part of their core curriculum were largely positive with added benefits of self-care.</p>","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"13 3","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12196255/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144486264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>\"Put Me in, Coach\"</i>: A Discussion of Deprescribing Roles, Responsibilities, and Motivations Based on a Qualitative Study with Healthcare Professional Students.","authors":"Devin Scott, Amy Hall, Rachel Barenie, Crystal Walker, Muneeza Khan, Paul Koltnow, William R Callahan, Alina Cernasev","doi":"10.3390/pharmacy13030077","DOIUrl":"10.3390/pharmacy13030077","url":null,"abstract":"<p><p>As the US population ages, the number of prescriptions managed by patients and healthcare teams is increasing. Thus, discontinuing or reducing medications that are considered to pose more risks than benefits can be achieved through deprescribing. Despite increasing calls for a stronger focus on deprescribing in healthcare education, current discussions highlight the lack of training on this topic within healthcare curricula. This is a significant barrier to effectively implementing the deprescribing process. This study aimed to characterize healthcare professional students (HPSs)'s perspectives on deprescribing within an interprofessional healthcare team, particularly regarding the motivations and roles of these future practitioners.</p><p><strong>Methods: </strong>Focus groups were conducted with HPSs at the University of Tennessee Health Science Center. The data collection, guided by a conceptual model, took place over three months in 2022. Data analysis was performed using thematic analysis, during which themes were identified through inductive coding.</p><p><strong>Results: </strong>Participants (<i>n</i> = 36) represented various faculties, including medicine, pharmacy, health professions, nursing, and dentistry. Two themes emerged: (1) Healthcare Team Members' Roles and Responsibilities (2) \"<i>Put Me in, Coach</i>\": Patient Safety Motivates Deprescribing.</p><p><strong>Conclusion: </strong>Data from HPSs highlighted the importance of an interprofessional healthcare team approach to deprescribing. Based on these insights, educators and practitioners should focus on establishing strong interprofessional healthcare teams that privilege open communication. Teams should consider deprescribing as a patient safety concern, as this may galvanize the team and provide additional motivation for performing the necessary work of deprescribing.</p>","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"13 3","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12196685/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144486255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}